An open-label, multi-center study to evaluate the 1 safety and phannacokinetics of IGSC 20% . administered for 6 months in subjects with primary immunodeficiency
Clinical Trial Grant
Administered By
Pediatrics, Allergy and Immunology
Awarded By
Grifols USA, LLC
Start Date
January 1, 2016
End Date
February 28, 2019
Administered By
Pediatrics, Allergy and Immunology
Awarded By
Grifols USA, LLC
Start Date
January 1, 2016
End Date
February 28, 2019